Alexander Katalinic1, Nora Eisemann, Annika Waldmann. 1. Institute of Social Medicine and Epidemiology, University Medical Center, Lübeck, Institute for Cancer Epidemiology e.V., University of L¨beck.
Abstract
BACKGROUND: Nationwide skin cancer screening was introduced in Germany in 2008. The positive results of a pilot project carried out in 2003-4 in the federal state of Schleswig-Holstein had implied that screening would lower the mortality from melanoma. METHODS: Data on the incidence of invasive malignant melanoma of the skin (MM; ICD-10: C43) were extracted from the databases of the Association of Population-based Cancer Registries in Germany (GEKID) and from the Schleswig-Holstein cancer registry. Mortality rates were extracted from the official cause-of-death statistics. RESULTS: With the beginning of nationwide screening in 2008, the age-standardized incidence rate in Germany increased by approximately 28% to 18.2 cases per 100 000 persons in 2010. In Schleswig-Holstein, the incidence fell after the pilot project ended and has been comparable to the nationwide incidence since 2008. For Germany overall, there has been no downward trend in MM mortality since the introduction of nationwide screening; in 2013, the mortality rate was 2.3 deaths per 100 000 persons per year. In the area of the pilot study, mortality declined to a level of 1.0/100 000/year until 2008 and then began to rise again. At present, the mortality due to MM in Schleswig- Holstein is once again the same as that in Germany overall (2.4/100 000/year). CONCLUSION: The introduction of nationwide skin cancer screening in 2008 has not yet led to any measurable decline in mortality due to melanoma. The current method of screening seems to be less thorough than that used in the pilot project; this may explain the absence of a decline in MM-related mortality in Germany overall up to the year 2013, as well as the rising mortality in Schleswig-Holstein since the end of the pilot program. The generation of a robust set of data on how skin cancer screening can be optimized now seems urgently necessary.
BACKGROUND: Nationwide skin cancer screening was introduced in Germany in 2008. The positive results of a pilot project carried out in 2003-4 in the federal state of Schleswig-Holstein had implied that screening would lower the mortality from melanoma. METHODS: Data on the incidence of invasive malignant melanoma of the skin (MM; ICD-10: C43) were extracted from the databases of the Association of Population-based Cancer Registries in Germany (GEKID) and from the Schleswig-Holstein cancer registry. Mortality rates were extracted from the official cause-of-death statistics. RESULTS: With the beginning of nationwide screening in 2008, the age-standardized incidence rate in Germany increased by approximately 28% to 18.2 cases per 100 000 persons in 2010. In Schleswig-Holstein, the incidence fell after the pilot project ended and has been comparable to the nationwide incidence since 2008. For Germany overall, there has been no downward trend in MM mortality since the introduction of nationwide screening; in 2013, the mortality rate was 2.3 deaths per 100 000 persons per year. In the area of the pilot study, mortality declined to a level of 1.0/100 000/year until 2008 and then began to rise again. At present, the mortality due to MM in Schleswig- Holstein is once again the same as that in Germany overall (2.4/100 000/year). CONCLUSION: The introduction of nationwide skin cancer screening in 2008 has not yet led to any measurable decline in mortality due to melanoma. The current method of screening seems to be less thorough than that used in the pilot project; this may explain the absence of a decline in MM-related mortality in Germany overall up to the year 2013, as well as the rising mortality in Schleswig-Holstein since the end of the pilot program. The generation of a robust set of data on how skin cancer screening can be optimized now seems urgently necessary.
Authors: Joanne F Aitken; Philippa H Youl; Monika Janda; John B Lowe; Ian T Ring; Mark Elwood Journal: Int J Cancer Date: 2006-02-15 Impact factor: 7.396
Authors: Markus P Anders; Sandra Nolte; Annika Waldmann; Marcus Capellaro; Beate Volkmer; Rüdiger Greinert; Eckhard W Breitbart Journal: Eur J Public Health Date: 2014-04-23 Impact factor: 3.367
Authors: Eckhard W Breitbart; Kohelia Choudhury; Markus P Anders; Beate Volkmer; Rüdiger Greinert; Alexander Katalinic; Jürgen Tacke; Ulrich Keilholz Journal: Oncol Res Treat Date: 2014-08-29 Impact factor: 2.825
Authors: Alexander Katalinic; Annika Waldmann; Martin A Weinstock; Alan C Geller; Nora Eisemann; Ruediger Greinert; Beate Volkmer; Eckhard Breitbart Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: A Waldmann; S Nolte; M A Weinstock; E W Breitbart; N Eisemann; A C Geller; R Greinert; B Volkmer; A Katalinic Journal: Br J Cancer Date: 2012-01-31 Impact factor: 7.640
Authors: M A Weinstock; J P Lott; Q Wang; L J Titus; T Onega; H D Nelson; L Pearson; M Piepkorn; R L Barnhill; J G Elmore; A N A Tosteson Journal: Br J Dermatol Date: 2017-03-01 Impact factor: 9.302
Authors: Mary K Tripp; Meg Watson; Sophie J Balk; Susan M Swetter; Jeffrey E Gershenwald Journal: CA Cancer J Clin Date: 2016-05-27 Impact factor: 508.702